

| | | | | | |
|------|---|---------------------|-----|-----------|------|
| 竹田 潔 | IL-12p40 and IL-18 in crescentic glomerulonephritis: IL-12p40 is the key Th1-defining cytokine chain, whereas IL-18 promotes local inflammation and leukocyte recruitment. | J. Am. Soc. Nephrol | 16 | 2023-2033 | 2005 |
| 竹田 潔 | B lymphocyte activation by human papillomavirus-like particles directly induces Ig class switch recombination via TLR4-MyD88. | J. Immunol | 174 | 7912-7919 | 2005 |
| 竹田 潔 | Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer. | J. Virol | 79 | 6741-6750 | 2005 |
| 竹田 潔 | PI3K integrates the action of insulin and leptin on hypothalamic neurons. | J. Clin. Invest | 115 | 951-958 | 2005 |
| 竹田 潔 | Down-regulation of dopamine transporter and abnormal behavior in STAT6-deficient mice. | Int. J. Mol. Med | 15 | 819-825 | 2005 |
| 竹田 潔 | Nonredundant roles of Sema4A in the immune system: Defective T cell priming and Th1/Th2 regulation in Sema4A-deficient mice. | Immunity | 22 | 305-316 | 2005 |
| 竹田 潔 | The nuclear I κ B protein I κ BNS selectively inhibits lipopolysaccharide-induced IL-6 production in macrophages of the colonic lamina propria. | J. Immunol | 174 | 3650-3657 | 2005 |
| 竹田 潔 | MyD88-deficient mice develop severe intestinal inflammation in dextran sodium sulfate colitis. | J. Gastroenterol | 40 | 16-23 | 2005 |
| 竹田 潔 | Roles of Stat3 and ERK in G-CSF Signaling. | Stem Cells | 23 | 252-263 | 2005 |
| 竹田 潔 | STAT6 deficiency inhibits tubulointerstitial fibrosis in obstructive nephropathy. | Int. J. Mol. Med | 15 | 225-230 | 2005 |
| 竹田 潔 | Differential roles of Toll-like receptors 2 and 4 in in vitro responses of macrophages to Legionella pneumophila. | Infect. Immun | 73 | 352-361 | 2005 |
| 竹田 潔 | The kinase domain of death-associated protein kinase is inhibitory for tubulointerstitial fibrosis in chronic obstructive nephropathy. | Int. J. Mol. Med | 15 | 73-78 | 2005 |
| 竹田 潔 | Both IL-12 and IL-18 contribute to small intestinal Th1-type immunopathology following oral infection with Toxoplasma gondii but IL-12 is dominant over IL-18 in parasite control. | Eur. J. Immunol | 34 | 3197-3207 | 2004 |
| 竹田 潔 | In vivo transfection of a cis element 'decoy' against signal transducers and activators of transcription 6 (STAT6)-binding site ameliorates IgE-mediated late-phase reaction in an atopic dermatitis mouse model. | Gene Ther | 11 | 1753-1762 | 2004 |
| 竹田 潔 | In vivo transfection of a cis element 'decoy' against signal transducers and activators of the transcription 6 (STAT6) binding site ameliorates the response of contact hypersensitivity. | Gene Ther | 11 | 1763-1771 | 2004 |

| | | | | | |
|-------|--|--|--------|-----------|------|
| 竹田 潔 | Toll-like receptors and their adaptors in innate immunity. | Cur. Med. Chem | 4 | 3-11 | 2005 |
| 竹田 潔 | Toll-like receptors in innate immunity. | Int. Immunol | 17 | 1-14 | 2005 |
| 竹田 潔 | Evolution and integration of innate immune recognition systems: the Toll-like receptors. | J. Endotoxin Res | 11 | 51-55 | 2005 |
| 竹田 潔 | Mechanism for recognition of CpG DNA. | Vaccine Adjuvants | | 71-87 | 2005 |
| 阿部千代治 | Synthesis of new sugar derivatives from <i>Stachys sieboldi</i> Miq and antibacterial evaluation against <i>Mycobacterium tuberculosis</i> , <i>Mycobacterium avium</i> , and <i>Staphylococcus aureus</i> . | Bioorganic & Medical Chemistry Letters | 17(9) | 2487-2491 | 2007 |
| 阿部千代治 | Evaluation of major membrane protein-II as a tool for serodiagnosis of leprosy. | FEMS Microbiol Lett | 272 | 202-205 | 2007 |
| 阿部千代治 | バクテックMGIT 960結核菌薬剤感受性検査用ミジットシリーズ (MGIT AST)および小川標準法によるイソニアジド低濃度薬剤感受性検査の判定不一致に関する検討 | 結核 | 82 | 449-454 | 2007 |
| 阿部千代治 | 結核菌薬剤感受性検査のためのBACTEC MGIT 960 ASTの評価:外部精度管理菌株を用いた研究 | 結核 | 81 | 57-62 | 2006 |
| 阿部千代治 | バクテックMGIT 960結核菌薬剤感受性検査の判定齟齬に関する検討 | 結核 | | | 印刷中 |
| 阿部千代治 | 結核菌の薬剤耐性に関与する遺伝子 | 結核 | 80 | 804-807 | 2005 |
| 阿部千代治 | Simple fibroblast-based assay to test the pyrazinamide susceptibility of <i>Mycobacterium tuberculosis</i> . | Antimicrob Agents Chemother | 49 | 804-807 | 2005 |
| 坂谷光則 | Molecular Epidemiology of <i>Mycobacterium tuberculosis</i> -Comparision between Multidrug-Resistant Strains and Pan-Sensitive Strains. | Kekkaku | 82(6) | 531-538 | 2007 |
| 坂谷光則 | Evaluation of a novel vaccine (HVJ-liposome / HSP65 DNA + IL-12 DNA) against tuberculosis using the cynomolgus monkey model of TB. | Vaccine | 25(16) | 2990-2993 | 2007 |
| 坂谷光則 | Development of vaccines and passive immunotherapy against SARS corona virus using SCID-PBL/hu mouse models. | Vaccine | 25(16) | 3038-3040 | 2007 |
| 坂谷光則 | Pulmonary <i>Mycobacterium avium</i> complex infection associated with the IVS8-T5 allele of the CFTR gene. | Int J Tuberc Lung Dis | 11(7) | 808-813 | 2007 |
| 坂谷光則 | Molecular epidemiological analysis of <i>Mycobacterium kansasii</i> isolates. | Kekkaku | 82(2) | 103 | 2007 |

| | | | | | |
|------|--|---|--------|-----------|------|
| 坂谷光則 | Novel Vaccination (HVJ-liposome / HSP65 DNA + IL-12 DNA) Against Tuberculosis Using Cynomolgus Monkey. | " 13 th International Congress of Immunology " Edit Jorge Kalil, Edecio Cunha-Neto, Luiz Viente Rizzo, MEDIMOUDI ntern | | 119-122 | 2007 |
| 坂谷光則 | DNA vaccine using hemagglutinating virus of Japan-liposome encapsulating combination encoding mycobacterial heat shock protein 65 and interleukin-12 confers protection against Mycobacterium tuberculosis by T cell activation. | Vaccine | 24 | 1191-1204 | 2006 |
| 坂谷光則 | Development of vaccines and passive immunotherapy against SARS corona virus using mouse and SCID-PBL/hu mouse models. | Adv Exp Med Biol | | 581-596 | 2006 |
| 坂谷光則 | Chemotherapy for pulmonary M.kansasii disease. | Kekkaku | 81 | 80-81 | 2006 |
| 坂谷光則 | Exogenous re-infection by multidrug-resistant tuberculosis. | Kekkaku | 81 | 41-43 | 2006 |
| 坂谷光則 | Incipient stage of pulmonary Langerhans-cell histiocytosis complicated with pulmonary tuberculosis was examined by high-resolution computed tomography. | Respir Med | 99(9) | 1188-1190 | 2005 |
| 坂谷光則 | The non-tuberculous mycobacteriosis. | Kekkaku | 80 | 25-30 | 2005 |
| 坂谷光則 | Novel recombinant BCG- and DNA-vaccination against tuberculosis in a cynomolgus monkey model. | Vaccine | 23 | 2132-2135 | 2005 |
| 坂谷光則 | The Development of vaccines against SARS Corona Virus in Mice and SCID-PBL/hu Mice. | Vaccine | 23 | 2269-2272 | 2005 |
| 坂谷光則 | Novel vaccination (HVJ-liposome/Hsp65 DNA+ IL-12 DNA and recombinant 72f BCG) against Tuberculosis using cynomolgus monkey. | 40 th Tuberculosis and Leprosy Research Conference | | 46-50 | 2005 |
| 坂谷光則 | 多剤耐性結核菌の院内感染の現状と対策 | 化学療法の領域 | 22 | 1691-1695 | 2006 |
| 坂谷光則 | 培養陰性、非結核性抗酸菌混在時における結核菌薬剤耐性遺伝子検査キットの有用性 | 臨床検査 | 50(8) | 934-939 | 2006 |
| 坂谷光則 | リファンピシン耐性Mycobacterium kansasiiにおけるrpoB変異の解明 | 結核 | 81(7) | 475-479 | 2006 |
| 鈴木克洋 | Hypervariable loci that enhance the discriminatory ability of newly proposed 15-loci and 24-loci variable-number tandem repeat typing method on Mycobacterium tuberculosis strains predominated by the Beijing family. | FEMS Microbiol Lett | 270(1) | 67-74 | 2007 |

| | | | | | |
|-------|--|---------------------------------|--------|-----------|------|
| 鈴木克洋 | Rapid detection of Mycobacterium tuberculosis in respiratory samples by transcription - reverse transcription concerted reaction with an automated system. | J. Clin. Microbiol | 43 | 5435-5439 | 2005 |
| 鈴木克洋 | Rapid detection of Mycobacterium tuberculosis in respiratory samples by transcription - reverse transcription concerted reaction with an automated system. | J. Clin. Microbiol | 43 | 5435-5439 | 2005 |
| 鈴木克洋 | 肺カンサシ症の治療 | 結核 | 81 | 41-43 | 2006 |
| 鈴木克洋 | リファンピシン耐性 Mycobacterium kansasiiにおけるrpoB 変異の解明 | 結核 | 81 | 475-479 | 2006 |
| 鈴木克洋 | 結核・非結核性抗酸菌症 非結核性抗酸菌症、わが国における最近の動向、病態：(露口泉夫編) | 最新医学 | | | 2006 |
| 鈴木克洋 | 培養陰性、非結核性抗酸菌混在時における結核菌薬剤耐性遺伝子検査キットの有用性 | 臨床検査 | 50(8) | 934-939 | 2006 |
| 鈴木克洋 | Mycobacterium kansasii株における分子疫学的解析 | 結核 | 82(2) | 103-110 | 2007 |
| 鈴木克洋 | バクテックMGIT960結核菌薬剤感受性検査用ミジットシリーズ(MGIT AST)および小川標準法によるイソニアジド低濃度薬剤感受性検査の判定不一致に関する検討 | 結核 | 82(5) | 449-454 | 2007 |
| 鈴木克洋 | 結核菌の分子疫学的解析 - 多剤耐性結核菌と全剤感受性結核菌の比較 - | 結核 | 82 | 531-550 | 2007 |
| 鈴木克洋 | わが国における結核の現状とクオンチフェロン検査 | Schneller | 62 | 20-25 | 2007 |
| 鈴木克洋 | 結核患者院内発生時の対応 - QuantiFERONの可能性も含めて | 感染症 | 37(3) | 105-108 | 2007 |
| 鈴木克洋 | 肺結核の典型像、非典型像 | 日本医事新報 | 4358 | 53-56 | 2007 |
| 鈴木克洋 | 肺非結核性抗酸菌症の画像所見 | 日本医事新報 | 4362 | 53-56 | 2007 |
| 鈴木克洋 | 非結核性抗酸菌症 | 小児科診療 | 71(1) | 83-88 | 2007 |
| 鈴木克洋 | 診療の秘訣「ツベルクリン反応の解釈」 | Modern Physician | 26 | 424 | 2006 |
| 鈴木克洋 | 肺結核を見落とさないために | 呼吸と循環 | 54 | 63-69 | 2006 |
| 鈴木克洋 | 肺非結核性抗酸菌症は増加している:臨床からみた病原性と宿主要因の考察 | 最新医学 | 61 | 258-265 | 2006 |
| 鈴木克洋 | 抗菌薬をつかいこなそう「結核」 | メディチーナ | 43(4) | 664-665 | 2006 |
| 鈴木克洋 | 多剤耐性結核菌の院内感染の現状と対策. | 化学療法の領域 | 22(11) | 1691-1695 | 2006 |
| 鈴木克洋 | 非結核性抗酸菌症 | Infectious Diseases Report 2006 | 37 | | 2006 |
| 鈴木克洋 | 結核患者の新しい退院基準について | M.P. | 23(11) | 1992-1993 | 2006 |
| 鈴木克洋 | 肺カンサシ症の治療 | 結核 | 81 | 41-43 | 2006 |
| 鈴木克洋* | 抗菌薬をつかいこなそう「結核」 | メディチーナ | 43(4) | 664-665 | 2006 |

| | | | | | |
|------|---|--------------------------------|--------|-----------|---------------|
| 鈴木克洋 | 質疑応答、肺MAC症の診断・治療 | 日本医事新報 | 4225 | 90-91 | 2005 |
| 鈴木克洋 | 病気と薬の説明ガイド2005 肺結核 | 薬局 | 56(1) | 899-905 | 2005 |
| 鈴木克洋 | 診療の秘訣「ツベルクリン反応の解釈」 | Modern Physician | 26(3) | 424 | 2005 |
| 鈴木克洋 | 私の処方「肺MAC症」 | Modern Physician | 25 | 1596 | 2005 |
| 松本 真 | Screening for Novel Antituberculosis Agents that are Effective Against Multidrug Resistant Tuberculosis. Current Topics in Medicinal Chemistry. | Curr Top Med Chem | 7(5) | 499-507 | 2007 |
| 松本 真 | OPC-67683, A Promising Drug Candidate to Combat Unmet Needs in TB Chemotherapy in vitro and in Mice. | PLoS Medicine | 3(11) | e466 | 2006 |
| 松本 真 | Selective delivery of rifampicin incorporated into poly(DL-lactic-co-glycolic) acid microspheres after phagocytotic uptake by alveolar macrophages, and the killing effect against intracellular Mycobacterium bovis Calmette-Guérin. | Microbes and Infection | 8 | 2484-2491 | 2006 |
| 松本 真 | Synthesis and Antituberculosis Activity of a Novel Series of Optically Active 6-Nitro-2,3-dihydroimidazo[2,1-b]oxazoles | Journal of Medicinal Chemistry | 49(26) | 7854-7860 | 2006 |
| 松本 真 | 新たな抗結核薬開発の必要性と世界の現状 | 化学療法の領域 | 22(11) | 1715-1722 | 2006 |
| 松本 真 | DNA augments antigenicity of mycobacterial DNA-binding protein 1 and confers protection against Mycobacterium tuberculosis infection in mice. | J Immunol | 175(1) | 441-449 | 2005 |
| 中島俊洋 | Evaluation of a novel vaccine (HVJ-liposome/HSP65 DNA+ IL-12 DNA) against tuberculosis using the cynomolgus monkey model of TB. | Vaccine. | 25(16) | 2990-2993 | 2007 |
| 中島俊洋 | Development of HVJ envelope vector and its application to gene therapy. | Adv Genet | 53 | 07-332 | 2005 |
| 小出幸夫 | Identification of HLA-A*0201-restricted T-cell epitope on MPT51 protein, a major secreted protein derived from Mycobacterium tuberculosis, using combination of MPT51 overlapping peptide library and computer algorithms. | Infect Immun | | | 2007 in press |
| 小出幸夫 | Intratracheal administration of third-generation lentivirus vector encoding MPT51 from Mycobacterium tuberculosis induces specific CD8+ T-cell responses in the lung. | Vaccine | | | 2007 in press |
| 小出幸夫 | Effective induction of anti-tumor immune responses with oligomannose-coated liposome targeting to intraperitoneal phagocytic cells. | Cancer Letters | | | 2007 in press |

| | | | | | |
|------|---|-------------------------------------|-----------|-----------|---------------|
| 小出幸夫 | In vivo hierarchy of individual T-cell epitope-specific helper T-cell subset against an intracellular bacterium. | Vaccine | | | 2007 in press |
| 小出幸夫 | Chemokine receptor-mediated delivery of mycobacterial MPT51 protein efficiently induces antigen-specific T-cell responses. | Vaccine | | | 2007 in press |
| 小出幸夫 | Intracytosolic Listeria monocytogenes induces cell death through caspase-1 activation in murine macrophages. | Cell Microbiol | | | 2007 in press |
| 小出幸夫 | Anti-infective vaccine strategies In: Liu D ed. | Handbook of Listeria Monocytogenes. | | | 2007 in press |
| 小出幸夫 | Immunization with dendritic cells loaded with γ -galactosylceramide at priming phase, but not at boosting phase, enhances cytotoxic T-lymphocyte activity against infection of intracellular bacteria. | FEMS Immunol Med Microbiol | 51 | 350-362 | 2007 |
| 小出幸夫 | Treatment with anti-TNF- α antibody infliximab reduces serum IL-15 levels in patients with rheumatoid arthritis. | Clin Rheumatol | 26(4) | 505-509 | 2007 |
| 小出幸夫 | Curcumin for maintenance therapy in ulcerative colitis (Letter). | Clin Gastroenterol Hepatol | 5 | 642 | 2007 |
| 小出幸夫 | Immunization with gene encoding granulocyte-macrophage colony-stimulating factor inserted with a single helper T-cell epitope of an intracellular bacterium induces a specific T-cell subset and protective immunity. | Vaccine | 24 | 4548-4553 | 2006 |
| 小出幸夫 | Immunization with dendritic cells retrovirally transduced with mycobacterial antigen 85A gene elicits the specific cellular immunity including cytotoxic T-lymphocyte activity specific to a dominant epitope on Antigen 85A. | Vaccine | 24 | 2110-2119 | 2006 |
| 小出幸夫 | Expression mapping by retroviral vector for CD8 ⁺ T cell epitopes: definition of a Mycobacterium tuberculosis peptide presented by H2-D ^d . | J Immunol Methods | 298 (1-2) | 21-34 | 2005 |
| 小出幸夫 | 私達の研究(56)「細胞内寄生細菌感染症をめぐってーワクチン研究およびイメージング解析による感染機構の解明ー」 | 化学療法の領域 | 23(11) | 101-112 | 2007 |
| 吉田栄人 | Development of vaccines and passive immunotherapy against SARS coronavirus using SCID-PBL/hu mouse models. | Vaccine | 25(16) | 3038-40 | 2007 |

| | | | | | |
|------|---|------------------|--------|-----------|----------------|
| 吉田栄人 | Evaluation of a novel vaccine (HVJ-liposome / HSP65 DNA + IL-12 DNA) against tuberculosis using the cynomolgus monkey model of TB. | | 25(16) | 2990-2993 | 2007 |
| 吉田栄人 | Hemolytic C-type lectin CEL-III from sea cucumber expressed in transgenic mosquitoes impairs malaria parasite development. | PLoS Pathogens | | | In press |
| 吉田栄人 | Inhibition of collagen-induced platelet aggregation by anopheline anti-platelet protein, a saliva protein from a malaria vector mosquito. | Blood | 111 | 2007-2014 | 2007 |
| 吉田栄人 | Novel approach toward infectious diseases--combating malaria by using genetically engineered mosquitoes. | Nippon Rinsho | 5 | 1715-1726 | 2007 |
| 吉田栄人 | Development of vaccines and passive immunotherapy against SARS corona virus using mouse and SCID-PBL/hu mouse models. | Adv Exp Med Biol | 581 | 561-566 | 2006 |
| 吉田栄人 | Robust salivary gland-specific transgene expression in Anophelesstephensi mosquito. | Insect Mol Biol | 15 | 403-410 | 2006 |
| 吉田栄人 | DNA vaccine using hemagglutinating virus of Japan-liposome encapsulating combination encoding mycobacterial heat shockprotein 65 and interleukin-12 confers protection against Mycobacterium tuberculosis by T cell activation. | Vaccine | 24 | 1191-1204 | 2006 |
| 吉田栄人 | Robust salivary gland-specific transgene expression in Anophelesstephensi mosquito. | Insect Mol Biol | 15(4) | 403-410 | 2006 |
| 吉田栄人 | DNA vaccine using hemagglutinating virus of Japan-liposome encapsulating combination encoding mycobacterial heat shockprotein 65 and interleukin-12 confers protection against Mycobacterium tuberculosis by T cell activation. | Vaccine | 24 | 1191-1204 | 2006 |
| 吉田栄人 | Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model. | Vaccine | 23 | 2132-2135 | 2005 |
| 吉田栄人 | The development of vaccines against SARS corona virus in mice and SCID-PBL/hu mice. | Vaccine | 23 | 2269-2272 | 2005 |
| 吉田栄人 | Glucose-6-phosphate dehydrogenase (G6PD) mutations in Cambodia: G6PD Viangchan (871G>A) is the most common variant in the Cambodian population. | J Hum Genet | 50 | 468-470 | 2005 |
| 吉田栄人 | マラリア防圧——遺伝子操作蚊からのアプローチ——(総説) | 治療 | | | 2007 in press. |

| | | | | | |
|------|--|-----------------------------|--------|-----------|----------|
| 吉田栄人 | マラリアコントロールへの新たな挑戦—遺伝子操作によるマラリア非媒介蚊作製—(総説). | Medical Bio | 4 | 70-77 | 2007 |
| 吉田栄人 | 遺伝子操作によるマラリアを媒介しないハマダラカの創出—新規マラリアコントロールへの挑戦— | 日本衛生動物学会誌(総説) | 57 | 249-254 | 2006 |
| 吉田栄人 | 遺伝子操作蚊を用いた蚊-マラリア原虫の寄生適応性解明—マラリアコントロールに向けての新規戦略— | 蚕糸・昆虫バイオティック(総説) | 75 | 161-166 | 2006 |
| 大原直也 | Evidence for association between a Toll-like receptor 4 gene polymorphism and moderate/severe periodontitis in the Japanese Population. | J Periodont Res | 42 | 541-545 | 2007 |
| 大原直也 | Efficacy of Recombinant BCG Vaccine Secreting IL-15/Ag85B fusion protein on Protection against Mycobacterium tuberculosis. | J Infect Dis | | | in press |
| 大原直也 | Analysis of amphotericin B-induced cell signaling with chemical inhibitors of signaling molecules. | Microbiology and Immunology | 50 | 337-348 | 2006 |
| 大原直也 | The hemoglobin receptor protein of Porphyromonas gingivalis inhibits receptor activator NF- κ B ligand-induced osteoclastogenesis from bone marrow macrophages. | Infection and Immunity | 74 | 2544-2551 | 2006 |
| 大原直也 | Mutant Escherichia coli enterotoxin as a mucosal adjuvant causes specific CD4+ and CD8+ T cells to produce IFN γ and TNF α in response to nasal killed-bacillus Catmette-Guerin vaccine in mice. | Vaccine | 24(17) | 3591-3598 | 2006 |
| 大原直也 | A phospholipase C inhibitor suppresses amphotericin B-induced production of proinflammatory cytokines. | Microbiol. Immunol | | | 2006 |
| 大原直也 | Hemoglobin receptor protein (HbR) of Porphyromonas gingivalis inhibits RANKL-induced osteoclastogenesis from bone marrow macrophages. | Infect. Immun | 74(5) | 2544-2451 | 2006 |
| 大原直也 | Superoxide dismutase-encoding gene of the obligate anaerobe Porphyromonas gingivalis is regulated by the redox-sensing transcription activator OxyR. | Microbiology | 152 | 955-966 | 2006 |
| 大原直也 | Dissecting the role of Rho-mediated signaling in contractile ring formation. | Mol. Biol. Cell | 17 | 43-55 | 2006 |
| 大原直也 | Porphyromonas gingivalis-induced platelet aggregation in plasma depends on Hgp44 adhesin but not Rgp proteinase. | Mol. Microbiol | 59 | 152-167 | 2005 |
| 大原直也 | Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model. | Vaccine | 23 | 2132-2135 | 2005 |

| | | | | | |
|------|---|-----------------------|--------|-----------|------|
| 大原直也 | Identification of a new membrane-associated protein which influences transport/maturation of gingipains and adhesions of Porphyromonas gingivalis. | J. Biol. Chem | 280 | 668-8677 | 2005 |
| 大原直也 | The novel stationary-phase-upregulated protein of Porphyromonas gingivalis influences the production of superoxide dismutase, thiol peroxidase and thioredoxin. | Microbiology | 151 | 841-853 | 2005 |
| 大原直也 | BCGを用いた抗酸菌の抗原性および病原性に関する研究 | 日本細菌学雑誌 | 60 | 349-356 | 2005 |
| 大原直也 | 結核 | 保健の科学 | 49 | 691-697 | 2007 |
| 倉島篤行 | Pulmonary Mycobacterium avium complex infection associated with the IVS8-T5 allele of the CFTR gene. | Int J Tuberc Lung Dis | 11(7) | 808-813 | 2007 |
| 倉島篤行 | Pulmonary Mycobacterium avium complex infection: association with NRAMP1 polymorphisms. | Eur Respir J | 30(1) | 90-96 | 2007 |
| 倉島篤行 | Rapid detection of Mycobacterium tuberculosis in respiratory samples by transcription-reverse transcription concerted reaction with an automated system. | J Clin Microbiol | 43 | 5435-5439 | 2005 |
| 倉島篤行 | 非侵襲性肺アスペルギルス症治療の新たな展開 | 結核 | 82 | 143-147 | 2007 |
| 倉島篤行 | 非結核性抗酸菌症の治療 | 診断と治療 | 95(11) | 2008-2014 | 2007 |
| 倉島篤行 | 気管支結核の現状 103例の解析 | 結核 | 82(8) | 647-654 | 2007 |
| 倉島篤行 | HIV感染症における結核感染診断に対してのQuantiFERON-TB第2世代の有用性についての検討 | 結核 | 82(8) | 635-640 | 2007 |
| 倉島篤行 | 高齢者の抗酸菌感染症 | 日本臨床 増刊3 | 65 | 490-494 | 2007 |
| 倉島篤行 | リファンピシンを含む結核治療におけるシクロスポリン投与量の検討 | 結核 | 82(7) | 563-567 | 2007 |
| 倉島篤行 | 非結核性抗酸菌症の治療 | 日本胸部臨床 | 66(7) | 549-557 | 2007 |
| 倉島篤行 | 肺癌と活動性肺抗酸菌症の合併 特徴と推移 | 日本呼吸器学会雑誌 | 45(5) | 382-393 | 2007 |
| 倉島篤行 | 抗結核薬副作用への対応 | 呼吸器科 | 11(4) | 383-389 | 2007 |
| 倉島篤行 | 非結核性抗酸菌症治療の展望 | 結核 | 82(3) | 195-199 | 2007 |
| 倉島篤行 | 非結核性抗酸菌症の診断と治療 | 日本医事新報 | 4321 | 105 | 2007 |
| 倉島篤行 | 肝硬変に合併した結核症例の検討 | 結核 | 81(7) | 457-465 | 2006 |

| | | | | | |
|------|--|---|--------|-----------|------|
| 倉島篤行 | 肺結核とアスペルギルス症. 最新医学・別冊 新しい診断と治療のABC 41、呼吸器6 結核・非結核性抗酸菌症 | 最新医学社 | | 227-238 | 2006 |
| 倉島篤行 | RifampicinのPharmacokineticsに対する食事の影響 | 臨床薬理 | 37(6) | 353-357 | 2006 |
| 倉島篤行 | 非結核性抗酸菌症 | Modern Physician | 26(3) | 385-388 | 2006 |
| 倉島篤行 | 非結核性抗酸菌症の治療 肺MAC症の治療 再排菌例の検討 | 結核 | 81(1) | 38-41 | 2006 |
| 倉島篤行 | 過敏性肺炎類似のびまん性陰影を呈した肺Mycobacterium avium症の1例 | 結核 | 81(1) | 19-23 | 2006 |
| 倉島篤行 | 目でみる症例 肺結核症 | 内科 | 96(6) | 1121-1126 | 2005 |
| 倉島篤行 | 肺結核 | クリニカ | 32(6) | 351-357 | 2005 |
| 倉島篤行 | 現在および近未来の結核に対する対応および問題点 | Current Concepts in Infectious Diseases | 24(3) | 6-9 | 2005 |
| 倉島篤行 | 非結核性抗酸菌症 | Medicina | 42(10) | 1720-1722 | 2005 |
| 倉島篤行 | 肺癌と活動性肺抗酸菌症の混在する病態の検討 | 結核 | 80(5) | 413-419 | 2005 |
| 倉島篤行 | 非結核性抗酸菌症の診断と治療 | JIM: Journal of Integrated Medicine | 15(5) | 398-402 | 2005 |
| 倉島篤行 | 気密空間における感染性疾患 | 日本胸部臨床 | 64(4) | 325-332 | 2005 |
| 倉島篤行 | 非結核性抗酸菌症 | 診断と治療 | 93(2) | 239-244 | 2005 |
| 矢野郁也 | Characterizaion of the fucosylation pathway in the biosynthesis of glycopeptidolipids from Mycobacterium avium complex. | J Bacteriol | 188 | 5515-5522 | 2007 |
| 矢野郁也 | Evaluation of membrane protein II as a tool for serodiagnosis of leprosy. | FEMS Microbiol Lett | 272 | 205-205 | 2007 |
| 矢野郁也 | New packaging method of mycobacterial cell wall using octaarginine-modified liposomes; Enhanced uptake by and immunostimulatory activity of dendritic cells. | J. Controlled Res. | 120 | 60-69 | 2007 |
| 矢野郁也 | Molecular and supramolecular structure related differences in toxicity and granulomatogenic activity of mycobacterial cord factor in mice. | Mycrob. Pathog. | 43(1) | 10-21 | 2007 |
| 矢野郁也 | Serological test and chest computed tomography findings in patients with MAC lung disease. | Eur. Respir. J. | 29 | 1217-1223 | 2007 |

| | | | | | |
|------|--|--------------------------------------|-----------|-----------|------|
| 矢野郁也 | Structural characterization of a specific glycopeptidolipid containing a novel N-acyl-deoxy sugar from Mycobacterium Intracellulare serotype 7 and genetic analysis of its glycosylation pathway. | J. Bacteriol | 189(3) | 1099-1108 | 2007 |
| 矢野郁也 | BCG vaccine elicits both T-cell mediated and humoral immune responses directed against mycobacterial lipid components. | Vaccine | 24(29-30) | 5700-5707 | 2006 |
| 矢野郁也 | Interferon-gamma independent formation of pulmonary granuloma in mice by injections with trehalose dimycolate (cord factor), lipoarabinomannan and phosphatidylinositol mannosides isolated from Mycobacterium tuberculosis. | Clinical and Experimental Immunology | 144(1) | 134-141 | 2006 |
| 矢野郁也 | Mycobacterial sulfolipid shows a virulence by inhibiting cord factor induced granuloma formation and TNF-alpha release. | Microbial Pathogenesis | 40(6) | 245-253 | 2006 |
| 矢野郁也 | Macrophage scavenger receptor down-regulates mycobacterial cord factor-induced proinflammatory cytokine production by alveolar and hepatic macrophages. | Microbial Pathogenesis | 40(4) | 171-176 | 2006 |
| 矢野郁也 | Identification of two subpopulations of Bacillus Calmette-Guerin (BCG) Tokyo172substrain with different RD16 regions. | Vaccine | 24(23) | 4969-4974 | 2006 |
| 矢野郁也 | Identification and characterization of the genes involved in glycosylation pathways of mycobacterial glycopeptidolipid biosynthesis. | Journal of Bacteriology | 188(1) | 86-95 | 2006 |
| 矢野郁也 | Involvement of mannose receptor in glycopeptidolipid-mediated inhibition of phagosome-lysosome fusion. | Microbiology and Immunology | 50(3) | 243-251 | 2006 |
| 矢野郁也 | Clinical and prognostic importance of serotyping Mycobacterium avium-Mycobacterium Intracellulare complex isolates in human immunodeficiency virus-negative patients. | J Clin Microbiol | 43(7) | 3150-8 | 2005 |
| 矢野郁也 | Diverse humoral immune responses and changes in IgG antibody levels against mycobacterial lipid antigens in active tuberculosis. | Microbiology | 151 | 2065-74 | 2005 |
| 矢野郁也 | Direct molecular mass determination of trehalose monomycolate from 11 species of mycobacteria by MALDI-TOF mass spectrometry. | Microbiology | 151 | 1443-52 | 2005 |
| 矢野郁也 | Modified multiplex PCR for identification of Bacillus Calmette-Guerin substrain Tokyo among clinical isolates. | Vaccine | 23(24) | 3099-102 | 2005 |
| 矢野郁也 | Bacillus calmette-guerin Tokyo172 substrain for superficial bladder cancer characterization and ant tumor effect. | J Urol | 173(5) | 1507-1 | 2005 |

| | | | | | |
|------|---|------------------------|-------|-------------|------|
| 矢野郁也 | Serotype-specific modulation of human monocyte functions by glycopeptidolipid (GPL) isolated from <i>Mycobacterium avium</i> complex. | Biol Pharm Bull | 28(2) | 335-9 | 2005 |
| 矢野郁也 | Use of glycopeptidolipid core antigen for serodiagnosis of mycobacterium avium complex pulmonary disease in immunocompetent patients. | Clin Diagn Lab Immunol | 12(1) | 44-51 | 2005 |
| 赤川清子 | Functional Heterogeneity of Colony-Stimulating Factor-Induced Human Monocyte-Derived Macrophages. | Respirology | 11 | S32-S36 | 2006 |
| 赤川清子 | Catalase plays a critical role in the CSF-independent survival of human macrophages via regulation of the expression of Bcl-2 family genes. | J. Biol. Chem | 280 | 41137-41145 | 2005 |

DNA vaccine using hemagglutinating virus of Japan-liposome encapsulating combination encoding mycobacterial heat shock protein 65 and interleukin-12 confers protection against *Mycobacterium tuberculosis* by T cell activation

Shigeto Yoshida^{a,**}, Takao Tanaka^b, Yoko Kita^b, Sachiko Kuwayama^b, Noriko Kanamaru^b,
Yumiko Muraki^b, Satomi Hashimoto^b, Yoshikazu Inoue^b, Mitsunori Sakatani^b,
Eiji Kobayashi^c, Yasufumi Kaneda^d, Masaji Okada^{b,*}

^a Division of Medical Zoology, Department of Infection and Immunity, Jichi Medical School, Tochigi 329-0498, Japan

^b Clinical Research Center, National Hospital Organization Kinki-chuo Chest Medical Center, Osaka 591-8555, Japan

^c Division of Organ Replacement Research, Center for Molecular Medicine, Jichi Medical School, Tochigi 329-0498, Japan

^d Division of Gene Therapy Science, Graduate School of Medicine, Osaka University, Osaka 565-0871, Japan

Received 11 January 2005; received in revised form 24 August 2005; accepted 25 August 2005
Available online 19 September 2005

Abstract

We investigated the immunogenicity and protective efficacy of DNA vaccine combinations expressing mycobacterial heat shock protein 65 (Hsp65) and interleukin-12 (IL-12) using gene gun bombardment and the hemagglutinating virus of Japan (HVJ)-liposome method. A mouse IL-12 expression vector (mIL-12 DNA) encoding single-chain IL-12 proteins comprised of p40 and p35 subunits were constructed. In a mouse model, a single gene gun vaccination with the combination of Hsp65 DNA and mIL-12 DNA provided a remarkably high degree of protection against challenge with virulent *Mycobacterium tuberculosis*; bacterial numbers were 100-fold lower in the lungs compared to BCG-vaccinated mice. To explore the clinical use of the DNA vaccines, we evaluated HVJ-liposome encapsulated Hsp65 DNA and mIL-12 DNA (Hsp65 + mIL-12/HVJ). The HVJ-liposome method improved the protective efficacy of the Hsp65 DNA vaccine compared to gene gun vaccination. Hsp65 + mIL-12/HVJ induced CD8⁺ cytotoxic T lymphocyte activity against Hsp65 antigen. Most importantly, Hsp65 + mIL-12/HVJ vaccination resulted in a greater degree of protection than that evoked by BCG. This protective efficacy was associated with the emergence of IFN- γ -secreting T cells and activation of proliferative T cells and cytokines (IFN- γ and IL-2) production upon stimulation with Hsp65 and antigens from *M. tuberculosis*. These results suggest that Hsp65 + IL-12/HVJ could be a promising candidate for a new tuberculosis DNA vaccine, which is superior to BCG vaccine.

© 2005 Elsevier Ltd. All rights reserved.

Keywords: Tuberculosis; DNA vaccine; HVJ-liposome

1. Introduction

Tuberculosis is a major global threat to human health, with about 2 million people dying each year from *Mycobac-*

terium tuberculosis infections. The only tuberculosis vaccine currently available is an attenuated strain of *Mycobacterium bovis* BCG. BCG continues to be widely administered to children in developing countries, yet its efficacy remains controversial, particularly against the pulmonary form of the disease in adults. In recent years, the increasing frequency of drug-resistant *M. tuberculosis* isolates has further complicated the clinical management of this disease. Clearly, a more effective vaccine for the control of tuberculosis is urgently needed.

* Corresponding author. Tel.: +81 72 252 3021; fax: +81 72 251 1372.

** Corresponding author. Tel.: +81 285 58 7339; fax: +81 285 44 6489.

E-mail addresses: shigeto@jichi.ac.jp (S. Yoshida),
okm@kch.hosp.go.jp (M. Okada).

It is well established that protective immunity to *M. tuberculosis* depends on both CD4⁺ and CD8⁺ T cells [1–6]. Because DNA vaccination results in the generation of cellular immune responses, including those of a Th-1-type response, and protection in animal models of infectious diseases [7,8]. In fact, several human clinical trials have recently been initiated to test the efficacy of DNA vaccines against emerging and re-emerging infectious diseases including hepatitis B [9], malaria [10,11] and HIV infections [12]. DNA vaccination has also shown potential for the development of tuberculosis vaccines in the mouse model [13–16]. However, in a guinea pig model, which is arguably one of the most biologically relevant systems available for studying human pulmonary tuberculosis, DNA vaccines has not proven more efficacious than BCG [17]. The efficacy of any experimental tuberculosis vaccine remains to be evaluated in human clinical trials and, thus, a vaccine against tuberculosis is still anxiously awaited.

Mycobacterial heat shock protein 65 (Hsp65) is a potential target for protective immunity and has been extensively studied [18]. Several groups have reported that *hsp65* DNA vaccines can induce strong protective immune responses in mice against virulent *M. tuberculosis* infections [19–21]. Protection is attributed to the establishment of a cellular immune response dominated by Hsp65-specific T cells that both produce IFN- γ and are cytotoxic towards infected cells. Furthermore, Lowrie et al. have reported that this vaccine reduces bacterial loads in mice infected with *M. tuberculosis* when given therapeutically after infection [22]. Interleukin-12 (IL-12) is a cytokine with a major role in the induction of IFN- γ -dominated immune responses to microbial pathogens. Orme and colleagues have demonstrated the importance of IL-12 in generation of the protective response to tuberculosis [23]. Co-administration of the IL-12 gene, which participates in the induction of IFN- γ dominated immune responses to microbial pathogens, with various tuberculosis DNA vaccines including the *hsp65* DNA [20,24] and 35 K MW DNA [25] may boost the efficacy of these DNA vaccines to levels achieved with BCG in the mouse model, although inhibitory effect rather than synergistic effect on immunotherapy was observed in mice co-administrated with *hsp65* DNA vaccine plus the *IL-12* gene.

In order to explore the preclinical use of tuberculosis DNA vaccine combinations of the *IL-12* DNA with the *hsp65* DNA, we chose the viral-based hybrid antigen delivery system hemagglutinating virus of Japan (HVJ)-liposome because this delivery system results in a high transfection efficacy, repeated gene transfection without reduction of gene transfer efficiency in vivo, and no apparent toxicity. These characteristics of HVJ-liposomes support the feasibility of its clinical application not only for cancer gene therapy but also for DNA vaccinations. In a recent study, highly efficient transfection of muscle cells was observed for several weeks when pcDNA3 plasmid containing the human tumor antigen genes, *MAGE-1* and *MAGE-3*, were encapsulated in HVJ-liposomes and injected intramuscularly into mice [26]. Effective induction

of CD4⁺ T cell responses by a hepatitis B core particle-based HIV vaccine was achieved by subcutaneous administration of HVJ-liposomes in mice [27]. HVJ-liposomes were also very effective as a mucosal vaccine against HIV infection [28]. Thus, it is likely that HVJ proteins may be responsible for inducing a robust immune response. No side effects from repetitive injections of HVJ-liposomes into mice, rats or monkeys were observed.

We designed this study to clarify the clinical feasibility of HVJ-liposome-mediated DNA vaccines for tuberculosis. First, we clarify that co-administration of IL-12 DNA with Hsp65 DNA via gene gun delivery enhanced protection in mice compared with Hsp65 DNA alone. Second, we show that vaccination with HVJ-liposome encapsulated Hsp65 DNA resulted in better protection than did gene gun vaccination. Third, we demonstrate that HVJ-liposome encapsulated Hsp65 DNA and IL-12 DNA induce enhanced protective immunity in the mouse model compared to that seen with BCG. This protective efficacy was associated with the emergence of IFN- γ -secreting T cells upon stimulation with Hsp65 and purified protein derivative. These results suggest that Hsp65 + IL-12/HVJ could be a promising candidate for a new tuberculosis DNA vaccine, which is superior to BCG vaccine. We also discuss in this paper the prospects of this HVJ-liposome-based DNA vaccine for testing in primate models [29] and, ultimately, in a clinical setting.

2. Materials and methods

2.1. Bacteria

M. tuberculosis strain H37Rv and *M. bovis* BCG Tokyo were kindly provided by Dr. I. Sugawara (JATA, Tokyo, Japan). *M. bovis* BCG Tokyo was maintained in synthetic Sauton medium (Wako Chemicals, Osaka, Japan). For the mouse infection studies, a single colony of *M. tuberculosis* H37Rv was grown in Middlebrook 7H9 (DIFCO Laboratories, Detroit, MI: lot 137971 XA MD) medium supplemented with albumin–dextrose complex and grown at 37 °C until approximately mid-log phase. Aliquots were stored at –80 °C and thawed at 10 days before use, grown to mid-log phase in 7H9 medium.

2.2. Reagents and antibodies

Purified protein derivative (PPD: lot T-3-4) was obtained from JAPAN BCG Co., Ltd. (Tokyo, Japan). Killed *M. tuberculosis* H37Ra (lot 13971XA) was obtained from DIFCO Laboratories. Fetal calf serum (FCS: lot AGC6341) was obtained from Hyclone (Logan, UT). Anti-L3T4, anti-Lyt2.2 monoclonal antibodies and anti-Thy1.2 antibody were kindly provided by Dr. K. Kuribayashi (Mie University, Tsu, Japan) and Dr. E. Nakayama (Okayama University, Okayama, Japan) [30].

2.3. Animals

Inbred and specific pathogen-free female BALB/c mice were purchased from Clea Japan Inc. (Tokyo, Japan). Mice were maintained in isolator cages, manipulated in laminar flow hoods and used between 8 and 10 weeks of age. Infected animals were housed in individual micro-isolator cages in a biosafety level (BL) 3 animal facility of the NHO Kinki-chuo Chest Medical Center.

2.4. Cell lines

COS-7 cells were kindly provided by Dr. H. Endoh (Jichi Medical School, Tochigi, Japan). COS-7 cells were maintained at 37 °C in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 10% FBS, 2 mM L-glutamine, and antibiotics. A mouse mastocytoma cell line (P815: DBA/2 origin) was kindly provided by Dr. C.S. Henney (Fred Hutchinson Cancer Research Center, Seattle) [31]. A mouse macrophage cell line (J774.1: BALB/c origin) was kindly provided by Dr. P. Ralph (Sloan Kettering Cancer Inst., New York, NY) [32]. The P815 and J774.1 cells were maintained in RPMI 1640 medium (Flow Laboratories, Inc., Mclean, VA) supplemented with 10% FCS, penicillin (100 U/ml), streptomycin (100 µg/ml) and 5×10^{-5} M 2-mercaptoethanol [33,34].

2.5. Plasmid construction

The *hsp65* gene was amplified from *M. tuberculosis* H37Rv genomic DNA by PCR using a set of primers, phsp65-F1 and phsp65-R1, and cloned into the *Bam*HI/*Not*I sites of pcDNA3.1 (+) (Invitrogen, San Diego, CA) to generate pcDNA-hsp65. pcDNA-hsp65 was designated as Hsp65 DNA in this text. For the construction of the *hsp65* gene fused with the mouse Igκ secretion signal sequence, the PCR product was cloned into the *Bam*HI/*Not*I sites of pcDNA-CS87 [35] to generate pcDNA-Ighsp65. pcDNA-Ighsp65 was designated as IgHsp65 DNA in this text. For the construction of the mouse IL-12 (mIL-12) *p40* and *p35* single-chain gene, the *mIL12p35* and *mIL12p40* genes were cloned from pcDNA-p40p35 [35] by PCR using sets of primers, pmIL12p35-F1 and pmIL12p35-R1, and pmIL12p40-F1 and pmIL12p40-R1, respectively, and cloned into pcDNA3.1 (+) to generate pcDNA-mIL12p40p35-F. pcDNA-mIL12p40p35-F was designated as mIL-12 DNA in this text. As a control, pcDNA-EGFP vector expressing the *EGFP* gene was used. Sequences of oligonucleotide primers used are available as request.

2.6. Protein production and antibody preparation

Recombinant Hsp65 (rHsp65) protein was expressed in *E. coli* BL21 (ΔDE3) and purified by affinity chromatography on Ni-NTA columns (Qiagen).

2.7. Transfection

DNA transfection of COS-7 cells was performed with the PolyFect Transfection Reagent (Qiagen) according to the manufacturer's instructions. After 24 h, supernatant and cells were harvested separately. Immunoprecipitation of cell lysates and supernatants with antibodies were performed as described previously [36]. Rat anti-mouse IL-12p70 (BD Biosciences Pharmingen, San Diego, CA) and mouse anti-rHsp65 polyclonal antibody were used for immunoprecipitation. For IL-12 bioassay, COS-7 cells (1×10^6 cells/plate) were plated into 60-mm cell culture plates and transfected with 2.5 µg of pcDNA 3.1, pcDNA-mIL12p40 + p35, or pcDNA-mIL12p40p35-F using the PolyFect Transfection Reagent. At 48 h after transfection, culture supernatants were collected and stored at -70 °C until use. Various volumes of the supernatants were added to the mouse spleen cells (2×10^6 cells/ml). Murine culture supernatants after 60 h incubation were collected and the level of mouse IFN-γ measured using sandwich ELISA kits (BD Opt EIA™ Set, BD Biosciences Pharmingen), according to manufacturer's instructions.

2.8. Vaccination

2.8.1. Gene gun vaccination

Gold particles coated with plasmid DNAs and their cartridges were prepared as described previously [35]. The abdomen was shaved and gold particles coated with plasmid DNA (1 µg plasmid DNA per shot) was delivered once into the abdomen using a Helios Gene gun (Nippon Bio-Rad Laboratory, Tokyo, Japan) at a helium discharge pressure of 300 psi. A separate group was vaccinated once subcutaneously with 1×10^6 colony-forming units (CFU) of *M. bovis* BCG Tokyo strain.

2.8.2. HVJ-liposome vaccination

HVJ-liposomes were prepared as described previously [37]. The HVJ-liposome complex was aliquoted with 10% DMSO and stored at -70 °C until use. HVJ-liposomes without plasmid DNA was used and designated as Empty/HVJ in this text. Groups of BALB/c mice were vaccinated three times at 3-week intervals with 100 µl of HVJ-liposome solution containing 50 µg of pcDNA-IgHsp65 and/or 50 µg of pcDNA-mIL12p40p35-F in the tibia both anterior muscles. A separate group was vaccinated once with 1×10^6 CFU *M. bovis* BCG Tokyo by subcutaneous injection at four different sites (left upper, right upper, left lower, right lower back) at the same time. HVJ-liposome DNA vaccines encapsulating pcDNA-IgHsp65, pcDNA-mIL12p40p35-F, or combination of pcDNA-IgHsp65 and pcDNA-mIL12p40p35-F was designated as IgHsp65/HVJ, mIL-12/HVJ, and IgHsp65 + mIL-12/HVJ, respectively, in this text.

2.9. Challenge infection of vaccinated animals and bacterial load determination

Mice were challenged by the intravenous route with 5×10^5 CFU of *M. tuberculosis* H37Rv 3 weeks after the third vaccination as described previously [38]. At 5 and 10 weeks after *M. tuberculosis* H37Rv challenge, the lungs, spleens, and livers were aseptically homogenized by using homogenizer in saline, and serial dilutions of the organ homogenates were plated on Ogawa agar (Kyokuto, Tokyo, Japan) or 7H11 Middlebrook agar (Kyokuto). Plates were sealed up and incubated at 37 °C and the number of CFU was counted 2 or 4 weeks later. Results are converted to log₁₀ values and log₁₀ [mean ± standard deviation (S.D.)] for CFU/organ/animal were calculated for each experimental group.

2.10. Histological analysis

The lungs were obtained from the mice, fixed with 10% buffered formalin, and embedded in paraffin. Each block was cut into 4 μm-thick sections and stained using hematoxylin and eosin. Semi-quantitative morphometric analysis of pathological slides was performed by our modified method of Dascher et al. [39] using a micrometer-attached microscope (Microphot-FXA, Nikon, Japan) [39,40]. The longer axis and minor axis of each granuloma in the field (×4 magnification) were measured. Longer axis to minor axis of each granuloma were multiplied and added up. Three random fields from each tissue section of mice and six random fields of guinea pigs were evaluated, and the average score of the fields was designated as the granuloma index (×10⁻² mm²). This method for the evaluation of granuloma area is significantly correlated with the granuloma area by other scanning method of hematoxylin and eosin section.

2.11. Tuberculosis-specific cytotoxic test using ⁵¹Cr release

Eight weeks after the final vaccination, CTL activity of spleen cells and mesenteric lymph node cells from vaccinated mice was assessed by using the ⁵¹Cr-release assay. P815 mastocytoma cells, which have the same major histocompatibility complex (MHC) (H-2^d) as BALB/c mice, were transfected with pcDNA-hsp65 and used as Hsp65 protein-expressing target cells. J774.1 macrophage cells were pulsed with *M. tuberculosis* (killed H37Ra) for 24 h and used as target cells. A total of 2×10^6 cells/ml effector splenic cells were treated with anti-CD8 antibody, anti-CD4 antibody or anti-Thy1.2 antibody followed by complement as described above. ⁵¹Cr release was assessed using the ⁵¹Cr-release assay [31,33] at the effector:target (E:T) ratio of 50:1. Spontaneous lysis (with medium alone) and maximum lysis (⁵¹Cr release after three cycles of freeze-thaw) were set up for background and targets.

Percent specific lysis was determined as:

$$\left[\frac{(\text{experimental release} - \text{spontaneous release})}{(\text{maximum release} - \text{spontaneous release})} \right] \times 100.$$

2.12. Proliferative responses of lymphocytes

Vaccinated mice were sacrificed immediately prior to challenge, and 1×10^5 single spleen cells were cultured in a 96-well flat bottom plate (Linbro) with rHsp65 protein (10 μg/ml) or PPD (20 μg/ml) for 60 h at 37 °C, and then pulsed with 1 μCi of [³H]thymidine per well for the final 12 h of incubation [30]. Cells were harvested onto glass wool fiber filters, and [³H]thymidine incorporation was measured using a Liquid Scintillation Counter LSC-6100 (ALOKA Co. Ltd., Tokyo, Japan).

2.13. Production of cytokines (IL-2 and IFN-γ)

Mouse cytokines were measured in quantitative ELISAs for IL-2 and IFN-γ as described previously [38]. Briefly, spleen cells from vaccinated mice were cultured at a concentration of 5×10^6 cells/ml in 200 μl of medium at various antigen concentrations. Culture supernatants were collected 48 h later and the levels of IFN-γ and IL-2 measured using sandwich ELISA kits (BD Opt EIA™), according to manufacturer's instructions.

2.14. ELISPOT assay

The spleens were removed aseptically from vaccinated mice three weeks after the third vaccination. Antigen-specific IFN-γ-producing cells were determined by ELISPOT as described previously [41]. Briefly, ELISPOT plates (MultiScreen IP Filtration plate MAIPS45; Millipore, Bedford, MA) were coated with anti-mouse IFN-γ MAb R4-6A2 (BD Biosciences Pharmingen). Spleen cells from vaccinated mice were suspended to 1×10^7 cells/ml (1×10^6 cells/well). In some experiments, the spleen cells from mice vaccinated with IgHsp65 + mL-12/HVJ were pre-incubated with anti-CD8 antibody or anti-CD4 antibody (1:50 dilution) for 15 min at 4 °C and then incubated with rabbit complement (1:10 dilution) (Cedarlane, Hornby, Ont., Canada) for 45 min at 37 °C as described previously [30,33]. The cells were placed in five wells into antibody-coated wells, and rHsp65 protein (10 μg/ml) or PPD (10 μg/ml) was added to each well. After 20 h of incubation at 37 °C, cells were removed by washing the plates, and the site of cytokine secretions was detected using biotinylated anti-mouse IFN-γ MAb XMG1.2 (BD Biosciences Pharmingen) and streptavidin-alkaline phosphatase conjugate (BD Biosciences Pharmingen). The enzyme reaction was developed with BCIP-NBT substrate (Vector Laboratories, Inc., Burlingame, CA). Spot-forming cells (SFCs) were enumerated using KS ELISPOT system (Carl Zeiss, Hallbergmoos, Germany).

2.15. Statistical analysis

Tukey–Kramer's HSD tests were used to compare \log_{10} value of CFU between groups following challenge and T cell responses between groups in ELISPOT assay. Student's *t* tests were performed to compare T cell responses between groups in T cell proliferation assay and granuloma formation between groups following challenge. A *P*-value of <0.05 was considered significant.

3. Results

3.1. In vitro expression of Hsp65 and IL-12

The DNA vaccines encoding mature and secreted forms of Hsp65 were constructed as Hsp65 DNA and IgHsp65 DNA, respectively. Hsp65 DNA contains the full-length *M. tuberculosis hsp65* gene. IgHsp65 DNA contains the full-length *M. tuberculosis hsp65* gene fused to the mouse Ig κ signal sequence. Each construct is driven by CMV promoter and terminated at a bovine growth hormone polyadenylation sequence. Hsp65 DNA or IgHsp65 DNA was transfected into COS-7 cells and cell lysates and supernatants were analyzed for the *hsp65* gene expression. As shown in Fig. 1A, the mature form was detected as a single band in cell lysates (lane 2), whereas the secreted form was detected as a doublet band in cell lysates (lane 3). The doublet of slightly higher molecular weight than the mature form is most likely due to incomplete cleavage of the Ig κ signal peptide in COS-7 cells because only a single band corresponding to the mature form was seen when HeLa cells or HepG2 cells were transfected with pcDNA-IgHsp65 (data not shown).

Based on the results of study reporting with high levels of IL-12 expression [42], we constructed a mouse IL-12 expression vector, mIL-12 DNA. The vector encodes mouse single-chain IL-12 protein comprised of p40 and p35 subunits linked by Gly₆Ser polypeptide linkers. As shown Fig. 1A, COS-7 cells transfected with mIL-12 DNA transiently expressed the mouse single-chain IL-12 protein with molecular weight of 80 kDa (lane 8). Quantitative analysis using ELISA showed that the COS-7 cells transfected with the mIL-12 DNA secreted four-fold higher levels of mIL-12p70 (125 ng/ml) than those transfected with from pcDNAmIL-12p40 + p35 (30 ng/ml), which previously constructed as a murine expression vector with IL-12 p40 and p35 expression cassettes in tandem array [35] (data not shown). Consistent with the mIL-12p70 expression level, the supernatant from the mIL-12 DNA transfectant cells induced 3.2-fold higher levels of IFN- γ from murine T lymphocytes than that from pcDNAmIL-12p40 + p35 transfectant cells (Fig. 1B). Thus, the mIL-12 DNA construct expresses biologically active IL-12, indicating that the single-chain IL-12 DNA is an effective DNA vaccine adjuvant capable of inducing primary Th-1 responses.

3.2. Evaluation of the best combination of Hsp65-based DNA vaccines with mIL-12 DNA for vaccine efficacy via gene gun

We compared the protective abilities of two versions of Hsp65-based DNA vaccine (Hsp65 DNA versus IgHsp65 DNA), and combinations with mIL-12 DNA (Hsp65 DNA versus Hsp65 DNA plus mIL-12 DNA, or IgHsp65 DNA versus IgHsp65 DNA plus mIL-12 DNA). Mice vaccinated with Hsp65 DNA, IgHsp65 DNA, and the combination with




Fig. 1. Expression and biological analysis of Hsp65 and mIL-12. (A) In vitro expression analysis of Hsp65 and mIL-12 from cells transiently transfected with DNA vaccines. COS-7 cells were transfected with EGFP DNA (lanes 1, 4 and 7), Hsp65 DNA (lanes 2 and 5), IgHsp65 DNA (lanes 3 and 6), and mILp40p35-F DNA (lane 8). Following metabolically labeling with [³⁵S]methionine, cell lysates (lanes 1, 2, 3, 7 and 8) and supernatants (lanes 4–6) were immunoprecipitated with mouse anti-Hsp65 polyclonal antibody (lanes 1–6) or rabbit anti-murine IL-12p70 antibody (lanes 7 and 8). (B) The biological activities of IL-12 expressed in transfected cell supernatants in vitro. Culture supernatants from COS-7 cells transfected with pcDNA3.1 (no insert empty vector), pcDNA-mIL12p40 + p35 or pcDNA-mIL12p40p35-F were added to the mouse spleen cells (2×10^6 cells/ml) at the final concentration of 4% (v/v) and incubated for 60 h. The levels of mouse IFN- γ were measured using sandwich ELISA kits as described in Section 2.




Fig. 2. The effect of a combination of mL-12 expression vector and Hsp65-based DNA vaccines and comparison of different vaccines on the protective efficacy against challenge with *M. tuberculosis*. Groups of mice were vaccinated once with Hsp65 DNA, IgHsp65 DNA and a combination of mL12 DNA via gene gun or three times with Hsp65/HVJ via intramuscular route and challenged intravenously with *M. tuberculosis* H37Rv as described in Section 2. Ten weeks after challenge, protection was measured by enumerating bacterial loads (CFU) in the lungs and spleen from vaccinated mice. Reduction of bacterial load was expressed as the mean log₁₀ difference in CFU in the organs of the naive and vaccinated mice. The statistical significance of differences between individual groups in the number of CFU was determined by Tukey–Kramer's HSD test ($n=4-5$). * and **, the statistical significance of differences ($P<0.05$ and $P<0.01$) compared to Hsp65 DNA + mL-12 DNA group, respectively; †, the statistical significance of differences ($P<0.01$) of IgHsp65 DNA + mL-12 DNA group compared to the naive, BCG, EGFP DNA, mL12 DNA, Hsp65 DNA and IgHsp65 DNA groups; §, the statistical significance of differences of Hsp65/HVJ group compared to BCG group ($P<0.05$) in the lungs; §§, the statistical significance of differences of Hsp65/HVJ group compared to Hsp65 DNA ($P<0.01$) and BCG ($P<0.05$) groups in the spleen.

mL-12 DNA via gene gun were challenged intravenously with *M. tuberculosis* H37Rv. The bacterial loads of the naive and vaccinated mice were compared 10 weeks after challenge (Fig. 2). Consistent with the previous report by Lima et al. [43], gene gun vaccination with Hsp65 DNA alone did not result in significant protective immunity as assessed by the bacterial load in the lungs or spleen. Vaccination with IgHsp65 DNA, which encodes the additional mouse Ig κ signal sequence upstream of the *hsp65* gene, did not significantly improve the protective efficacy in the bacterial load in the lungs, although there was a modest decrease in the bacterial load in the spleen. In contrast, the combination with mL-12 DNA markedly improved the protective efficacy both in the lungs and spleen ($P<0.01$). In particular, vaccination of IgHsp65 DNA plus mL-12 DNA conferred the greatest reduction of the bacterial load both in the lungs and spleen. Similar to IgHsp65 DNA plus mL-12 DNA, the increased

protection in the lungs and spleen was also observed in mice vaccinated with Hsp65 DNA plus mL-12 DNA compared to IgHsp65 DNA alone and mL-12 DNA alone. Thus, a strong synergistic effect on protection was achieved when Hsp65 DNA was co-administrated with IL-12 DNA. It is notable that the prophylactic effect of IgHsp65 DNA plus mL-12 DNA in the lungs was more than 100-fold greater than that of BCG. These vaccinations of IgHsp65 DNA plus mL-12 DNA and Hsp65 DNA plus mL-12 DNA also exerted the significant reduction in the liver compared to the naive ($P<0.05$) and control EGFP DNA groups ($P<0.01$), whereas there was no significant difference of the naive group compared with Hsp65 or mL-12 group (data not shown). In mice vaccinated with IgHsp65 DNA plus mL-12 DNA, increased protection in the lungs were also observed at 5 weeks after challenge, which was equivalent to that obtained by vaccination with BCG (data not shown).




Fig. 3. Mouse protection studies using HVJ-liposome vaccines. Groups of mice vaccinated with HVJ-liposome DNA or BCG were challenged by intravenous injection with *M. tuberculosis* H37Rv. Five weeks after challenge, protection was measured by enumerating the bacterial loads (CFU) in the lungs (A) and spleen (B) from vaccinated mice. Results are expressed as the mean log₁₀ ± S.D. of CFU. The statistical significance of differences between individual groups in the number of CFU was determined by Tukey–Kramer's HSD test ($n=4-5$). * $P<0.05$; ** $P<0.01$; †, the statistical significance of differences ($P<0.05$) of mIL-12/HVJ group compared to BCG, Empty/HVJ, and Hsp65/HVJ groups in the lungs; ††, the statistical significance of differences ($P<0.05$) of mIL-12 DNA group compared to Empty/HVJ group in the spleens.

3.3. Comparison of the protective efficacy of gene gun versus HVJ-liposome delivery of Hsp65 DNA vaccines

We next compared methods of DNA vaccine delivery on vaccine efficacy at 10 weeks after challenge. Hsp65/HVJ vaccination and challenge experiments were conducted simultaneously with gene gun experiments. As shown in Fig. 2, Hsp65/HVJ vaccination significantly reduced the bacterial loads as compared to Hsp65 gene gun immunization in the spleen ($P<0.01$). IgHsp65 gene gun immunization significantly reduced the bacterial loads as compared to Hsp65 gene gun immunization in the spleen ($P<0.05$, data not shown). Therefore, we used IgHsp65/HVJ for further experiments.

3.4. Protective efficacy of HVJ-liposome DNA vaccines

At 5 and 10 weeks after intravenous challenge of *M. tuberculosis* H37Rv, the number of CFU in the lungs, spleen, and liver were determined. Fig. 3 shows the results of bacterial loads 5 weeks after challenge. Vaccination with mIL-12/HVJ group resulted in significant protective immunity in the bacterial as compared to BCG, Empty/HVJ and Hsp65/HVJ groups

in the lung ($P<0.05$) and as compared to Empty/HVJ group in the spleen ($P<0.05$). Vaccination with IgHsp65+mIL-12/HVJ induced better protective immunity in the bacterial load both in the lungs and spleens than IgHsp65/HVJ alone and mIL-12/HVJ alone. Thus, the synergistic effect of IgHsp65 DNA and mIL-12 DNA resulted in improving the protective efficacy. At 10 weeks after challenge, the same reduction was also observed in these organs from mice vaccinated with IgHsp65+mIL-12/HVJ (data not shown). Body weights of vaccinated mice were similar in all vaccinated groups. Tissue weight of lungs, liver, and spleen in the IgHsp65+mIL-12/HVJ group were slightly lower than that from the naive mice (data not shown). In this experiment, BCG vaccination did not provide significant reduction of the bacterial load compared to the naive group. This may be due to the single-dose of vaccination used usually, the use of BCG Tokyo strain requires a three-dose vaccination to achieve 10 to 30-fold reduction of the bacterial loads compared to a non-vaccinated group. Although, 5 weeks after challenge, no reduction of bacterial loads was observed in IgHsp65/HVJ group compared with the naive control group, we confirmed the increased protection 10 weeks after challenge compared with the naive control group




Fig. 4. Histopathological analysis of vaccinated mice 10 weeks after *M. tuberculosis* challenge. Representative photomicrographs of lung tissue sections harvested from the naive control group (A) and from the IgHsp65 + mIL-12/HVJ group (B) are shown (10 weeks after *M. tuberculosis* challenge, hematoxylin and eosin staining, $\times 10$ objective). There were much infiltration of mononuclear cells and extensive parenchymal destruction by large, poorly demarcated granuloma in the lung from the naive control group. In the IgHsp65 + mIL-12/HVJ group, the lungs were less inflamed and only a few granuloma was observed. (C) Granuloma index of the naive control group and the IgHsp65+mIL-12/HVJ group in the lungs. Results are expressed as the mean \pm S.D. of triplicates of five mice per group. The statistical significance of differences between the groups was determined by Student's *t*-test. * $P < 0.05$ as compared with the naive control group.

at the same experiments (data not shown). These results indicate that co-vaccination with IL-12 DNA was effective for inducing protective immunity at as early as 5 weeks after challenge.

3.5. IgHsp65 + mIL-12/HVJ vaccination markedly reduced granuloma formation in the lung

In addition to the reduction of bacterial loads, the effects of vaccination on the mice were assessed by histological analysis. The granulomatous lesions in the lungs from IgHsp65 + mIL-12/HVJ mice were significantly less in number and size than from the naive control group (Fig. 4A and B). Quantitative evaluation of the granulomatous lesions clearly shows that IgHsp65 + mIL-12/HVJ vaccinated mice group exhibited significant reduction in granuloma index in the lungs, compared to the naive group ($P < 0.05$) (Fig. 4C). Thus IgHsp65 + mIL-12/HVJ vaccine provided significant

protection against the pulmonary pathology caused by *M. tuberculosis* infection.

3.6. HVJ-liposome DNA vaccines generated T-helper response and cytokine production

To investigate lymphocyte proliferative and cytokine responses induced by HVJ-liposome DNA vaccines, spleen cells from vaccinated mice were re-stimulated with antigen in vitro. As shown in Fig. 5, substantial lymphocyte proliferation was observed in response to rHsp65 protein in spleen cells from mice vaccinated with IgHsp65/HVJ or IgHsp65 + mIL-12/HVJ but not with the naive control. IgHsp65 + mIL-12/HVJ vaccination induced significantly better proliferative response to rHsp65 protein than did IgHsp65/HVJ vaccination ($P < 0.01$). In addition to lymphocyte proliferative responses, vaccination with IgHsp65 + mIL-12/HVJ induced elevated levels of IFN- γ and